Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 4, 2014, Pages 261-263

  von Haehling, Stephan ^a,b   Anker, Stefan D ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Epidemiology; Prevalence; Treatment; Wasting

Indexed keywords

ANAMORELIN; BIOCHEMICAL MARKER; ENOBOSARM;

BIOSYNTHESIS; BODY MASS; BODY WEIGHT; CACHEXIA; CATABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; EDITORIAL; EXERCISE; FATIGUE; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; INCIDENCE; INFLAMMATION; MORTALITY; MUSCLE MASS; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; WEIGHT REDUCTION;

EID: 84951560065     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-014-0164-8     Document Type: Editorial

References (16)

1. Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drugs Context. 2014;3:212265.
2. Anker SD, von Haehling S. Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention. J Cachexia Sarcopenia Muscle. 2014;5:171–6.
3. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14:754–62.
4. Katz AM, Katz PB. Diseases of the heart in the works of Hippokrates. Br Heart J. 1962;24:257–64.
5. Müller H. Atemschaukel. München; 2009.
6. Mauri D, Tsiara A, Valachis, Kalopita K, Tsali L, Tolis P, et al. Cancer cachexia: global awareness and guideline implementation on the web. BMJ Support Palliat Care. 2013;3:155–60.
7. Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, et al. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. PLoS One. 2014;9:e108687.
8. Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, et al. Relationships between right ventricular function, body composition and prognosis in heart failure. J Am Coll Cardiol. 2013;62:1660–70.
9. Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34:512–9.
10. von Haehling S, Doehner W, Springer J, Anker SD. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol. 2013;45:2257–65.
11. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.
12. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.
13. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.
14. Farkas J, von Haeling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013;4:173–8.
15. von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. Int J Cardiol. 2014;in press. doi:10.1016/j.ijcard.2014.10.026.
16. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.